In the year coming to an end soon, millions upon millions of Danish kroner have poured into a number of Danish life science firms to such a degree that 2021 has become the best year for raising capital in the domestic industry ever.
This is apparent just a few days before the clocks strike midnight on New Year's Eve, welcoming a 2022 that has the potential to become another record-breaking year for the Danish life science industry, though some dangers and wildcards loom on the horizon.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.